ULTRAGENYX WINS FDA APPROVAL FOR PEDIATRIC GENE THERAPY FOR SANFILIPPO SYNDROME - SEEKINGALPHA
FDA approval for pediatric gene therapy targeting Sanfilippo syndrome drives high-priority biotech catalyst.
What changed
FDA approval for pediatric gene therapy targeting Sanfilippo syndrome drives high-priority biotech catalyst.
Why it matters
FDA approval for pediatric gene therapy targeting Sanfilippo syndrome drives high-priority biotech catalyst. — impact context not separately stored; see What changed.
← Dashboard
Sep 17, 2026 07:49 PM ET